PDX Model Cohort
Acute Myeloid Leukemia PDX Models
Advance your Acute Myeloid Leukemia (AML) therapeutic candidates using a bank of rare and meticulously curated Acute Myeloid Leukemia models directly established from primary tumors.
Summary
Champions Oncology has developed a cutting-edge cohort of Acute Myeloid Leukemia (AML) models, delivering a full-spectrum approach to leukemia research. Our hematologic malignancy bank consists of 45* Acute Myeloid Leukemia models, encompassing most known subtypes. By using primary patient-derived samples and engrafting them systemically, we maintain the original molecular and clinical traits while mitigating genetic drift that often arises in passaged models.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading Acute Myeloid Leukemia cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to a largest engraftable bank of Acute Myeloid Leukemia models with clinically relevant molecularand pathological characteristics on the market.
AML Engraftment Assessement using Champions' Standard systemic AML In Vivo engraftment panel: CD3, CD33, CD34,CD38, mCD45, hCD45, CD117, CD123, Viability Dye.
Access to highly characterized AML models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
Includes models pretreated with advanced therapies like Cytarabine, Gilteritinib, 5-azacitidine, Stem cells transplant and more.
Champions' never-passaged patient AML models enable testing of therapeutic agents without the risk of clonal selection that could impact the clinical relevance of AML models.